<DOC>
	<DOCNO>NCT02679105</DOCNO>
	<brief_summary>The study evaluate safety effect intralymphatic allergen specific immunotherapy increase dos . Patients already undergone subcutaneous immunotherapy treat three intralymphatic injection increase dos ; 1000 SQ-U , 3000 SQ-U 10 000 SQ-U , placebo .</brief_summary>
	<brief_title>Intralymphatic Immunotherapy Increasing Doses , After Subcutaneous Immunotherapy</brief_title>
	<detailed_description>38 patient seasonal allergic rhinitis recently ( within 20 month ) end full subcutaneous immunotherapy protocol birch grass allergen improvement full symptom relief recruit . Study subject randomize intralymphatic injection placebo ALK Alutard 5-grasses birch .</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<criteria>Age 1855 Accepted sign informed consent . Recently ( within 20 month ) end full 3 year program subcutaneous immunotherapy ( SCIT ) amelioration symptom full symptom relief . Previously subcutaneous immunotherapy ( SCIT ) total symptom relief . Previously SCIT symptom improvement . Sensitizations house dust mite furry animal , symptom . Severe atopic dermatitis . Patients significant disease allergic rhinitis . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study . Patients respiratory tract infection past 4 week prior Visit 2 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( i.e. , oral contraceptive , intrauterine device , diaphragm , subdermal implant ) . Known autoimmune collagen disease Cardiovascular disease Perennial pulmonary disease include asthma Hepatic disease Known renal insufficiency Cancer Hematologic disease Chronic infectious disease Any medication possible sideeffect interfere immune response Previous immuno chemotherapy , apart SCIT Disease condition render treatment anaphylactic reaction difficult ( symptomatic coronary heart disease , severe arterial hypertension treatment Î²blockers ) Major metabolic disease Known suspect allergy study product Obesity BMI &gt; 30 since subcutaneous fat make ultrasound image lymph node harder may risk correct placement injection . Patients , opinion investigator , abuse alcohol drug within 2 year prior Visit 1 . Patients take investigational drug within 1 month six half life , whichever great , prior Visit 1 . Mental incapability cop study Withdrawal inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>